Login
$MCRB
$1.50 +$0.10 (7.14%) Live

$MCRB SEC Filings

Filed On Filing
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)

26 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

21 Aug 2026 EFFECT
18 Aug 2026 Form 4: Brady Kelly, See Remarks

Received 181 shares by exercise or conversion · Sold 64 shares ($291)

18 Aug 2026 Form 4: Shaff Eric D., Director

Received 722 shares by exercise or conversion · Sold 263 shares ($1.2K)

18 Aug 2026 Form 4: Henn Matthew R, See Remarks

Received 238 shares by exercise or conversion · Sold 81 shares ($369)

18 Aug 2026 Form 4: DesRosier Thomas, See Remarks

Received 245 shares by exercise or conversion · Sold 82 shares ($373)

13 Aug 2026 S-3
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS

04 Aug 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

This STOCK ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of July 31, 2026 by and between Seres Therapeutics, Inc., a Delaware corporation (the “Company”), and BMR-SIDNEY RESEARCH CAMPUS LLC, a Delaware limited liabili...

04 Aug 2026 424B5
10 Jul 2026 Form 4: Graves Kurt, Director

Granted 6,500 Stock Option (right to buy)

10 Jul 2026 Form 4: Kender Richard N, Director

Granted 50,000 Stock Option (right to buy)

10 Jul 2026 Form 4: Fraser Claire, Director

Granted 6,500 Stock Option (right to buy)

10 Jul 2026 Form 4: Dere Willard H, Director

Granted 6,500 Stock Option (right to buy)

10 Jul 2026 Form 4: Ausiello Dennis A, Director

Granted 6,500 Stock Option (right to buy)

10 Jul 2026 Form 4: Berenson Stephen, Director

Granted 6,500 Stock Option (right to buy)

10 Jul 2026 Form 4: DesRosier Thomas, See Remarks

Granted 7,500 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support